Skip to main content
NCBI home page
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2025 May 14.
Published in final edited form as: NeuroImmune Pharm Ther. 2024 Mar 6;3(2):129–137. doi: 10.1515/nipt-2024-0004

Neuroprotective Mushrooms

Mai M Abdelmoaty 1, Rana Kadry 1,2, R Lee Mosley 1, Howard E Gendelman 1,*
PMCID: PMC12077610  NIHMSID: NIHMS2071445  PMID: 40370689

Abstract

Alternative medicines commonly supplement or, at times, replace standard medical treatment. One area of increasing attention is disease-modifying medicines for neurodegenerative diseases. However, few such alternatives have been investigated thoroughly with an eye toward understanding mechanisms of action for clinical use. Medicinal mushrooms have important health benefits and pharmacological activities with anti-inflammatory, antioxidant, antibacterial, antiviral, immunomodulatory, digestive, cytoprotective, homeostatic, and neuroprotective activities. Edible mushrooms are known to play roles in preventing age-related diseases. Several studies have revealed that polysaccharides, terpenes, and phenolic compounds are chemical components derived from mushrooms with pharmacological activities. Due to limited effective protocols for mushroom protein extraction for proteomic studies, information about these medicinally related proteins and their biological functions remains enigmatic. Herein, we have performed proteomic studies of two mushroom species Laricifomes officinalis (agarikon) and Grifola frondosa (maitake). These studies serve to uncover a foundation for putative proteome-associated neuroprotective processes. The recovered proteins from both species show multiple cell-specific signaling pathways including unfolded protein response, and mitochondrial protein import as well as those linked to BAG2, ubiquitination, apoptosis, microautophagy, glycolysis, SNARE, and immunogenic cell signaling pathways. This study uncovered mushroom proteome-associated proteins which serve to better understand the structural and functional properties of mushrooms used as alternative medicines for broad potential health benefits.

Keywords: mushroom, agarikon, maitake, proteome, neuroprotection

Introduction

Neurodegenerative diseases include, but are not limited to, Alzheimer’s and Parkinson’s diseases (AD and PD), Huntington’s disease (HD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS). Neurological disorders are the leading cause of global physical and cognitive disability, and currently affect approximately 15% of the worldwide population [1]. In addition to direct costs associated with medical management of neurodegenerative diseases, indirect costs are associated with job loss, caregivers, medical equipment, and home safety [2]. Currently, available medications are palliative. No current therapies can halt or reverse cognitive or motor dysfunctions.

While multiple natural materials have been touted to positively affect the course of disease by possessing bioactive components, there is limited to no evidence that any protects or ameliorates disease. One example is edible mushrooms that are a known source of bio-compounds that have nutritional, pharmacological, and medicinal values [3]. For example, the fruiting body and dried mycelium extract of different mushrooms contain potential therapeutic components [4]. Moreover, prior studies showed that mushrooms do have antioxidative, anti-inflammatory, immunomodulatory, antimicrobial, and anticancer properties [5–7]. Thus, the consumption of mushrooms could potentially boost immune responses or affect the signs and symptoms of disease [8]. Notably, mycelium extracts and isolated bioactive compounds (melatonin, ergosterol, terpenoids, and phenolic compounds) extracted from mushrooms have been observed to demonstrate a spectrum of ameliorating effects on AD. These include, but are not limited to, neuroprotective and anti-inflammatory activities. Mushrooms from fungi such as Grifola frondosa, Lignosus rhinocerotis, Hericium erinaceus, may positively affect cognitive functions [9]. The aqueous extract of Ganoderma lucidum (500 mg/mL) was found to recover the synaptic dysfunction in rat cortical neurons via c-Jun N-terminal kinase (JNK) and P38 kinase pathway [10]. Furthermore, microglial activation has been significantly inhibited by Ganoderma lucidum extract, and consequently, reduced the dopaminergic neuron death in PD [11]. Mushrooms’ diverse biological functions that help to prevent age-based neuronal dysfunctions have received widespread attention. Studies have begun to identify mushroom’s active compounds [9, 12, 13]. This may be only a beginning in discovery toward implementation as research continues to seek alternative remedies through mycotic medicines.

Over the past decades, proteomic studies have been developed and used to study protein content amongst a broad variety of cells, tissues, and organisms, and notably have achieved relevancy in works to discover mycotic medicines [3]. These studies were performed to identify mushroom proteins with potential as antioxidant, anti-inflammatory, anticancer, anti-diabetic, antimicrobial, and apoptotic effectors. The use of proteomics for identification of fungal homologs with relevance to human function remains a challenge due to limitations in precisely identifying human proteins and extended efforts to obtain a complete proteome [14]. In our efforts to uncover the proteomic signature of mushrooms and putative activities, we utilized label-free quantification (LFQ) mass spectrometry-based methods to identify the proteins in the fruiting bodies of both Laricifomes officinalis (agarikon) and Grifola frondosa (maitake). We performed functional and pathway enrichment analyses of the relevant identified proteins. The data began to unravel a spectrum of linked biological processes, molecular functions, and immune responses that point to novel neuroprotective mushroom biological activities.

Materials and Methods

Materials

Fruiting bodies of the fungal species, Laricifomes officinalis (agarikon) and Grifola frondosa (maitake), used in this research were obtained from Mushroom Design (US) and Beond Ibogaine for trauma and addiction (Mexico). All reagents used for proteomic analyses were high-performance liquid chromatography (HPLC), or liquid chromatography - mass spectrometry (LC-MS) grade reagents.

Methods

Protein extraction

Ten grams of powdered fruiting bodies were used for each protein extraction and were performed in triplicate for each species. Trichloroacetic acid (TCA) /acetone precipitation method was performed as previously described [14]. The freeze-dried fresh sample was put into a mortar and ground into fine powder in the presence of liquid nitrogen. The fine powder was then homogenized in extraction buffer containing 0.1 M Tris-HCl (Fisher BioReagents, BP1758), 10 mM ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich, 79884), 1% polyvinylpolypyrrolidone (PVPP, Sigma-Aldrich, 77627), 0.4% β-mercaptoethanol (Sigma-Aldrich, M-3148) for 30 minutes (min). Afterwards, mixtures were centrifuged at 20,000 g for 20 min at 4°C using Sorvall LYNX 4000 Superspeed Centrifuge (Thermo Fisher Scientific, 75006580). Following centrifugation, the liquid phase was precipitated with 4 volumes of 20% TCA (Sigma-Aldrich, T0699) for 20 min at −20°C, then centrifuged at 20,000 g for 20 min at 4°C. The precipitate was then collected, suspended in 80% acetone (Sigma-Aldrich, 1.00020), and centrifuged at 20,000 g for 20 min at 4°C. Precipitation, collection, suspension, and centrifugation was repeated 7 times. The acetone was volatilized after the last centrifugation inside a chemical safety hood, and protein extract was stored at −80°C.

Proteomic analysis

Protein extracts were suspended in lysis buffer of 0.1 M Tris-HCL, 6 M urea (Avantor, 97063–802), 3 M thiourea (Sigma-Aldrich, T7875), 4% 3-[(3- cholamidopropyl) dimethylammonio] propanesulfonate (CHAPS, Thermo Fisher Scientific, 28300), 100 mM dithiothreitol (DTT, Promega, V3151), 2% Pharmalyte (Sigma-Aldrich, GE17–0456-01), and protease and phosphatase inhibitor cocktail (Thermo Fisher Scientific, 0078441), and the pH of buffer was adjusted to 8.0. Protein concentration was determined using Pierce 660 Protein Assay kit (Thermo Fisher Scientific, 22662) according to the manufacturer’s instructions. Afterward, samples were processed as previously described (29) using filter-aided sample preparation (FASP, Pall Life Sciences, OD010C34) to digest 60 μg per column (3 columns/sample). Following trypsin digestion overnight, samples were cleaned using the Oasis MCX column (Waters, 186000252). Cleaned peptides were then quantitated using NanoDrop2000 at λ=205 nm. Following resuspension in 0.1% formic acid, 10 μL of each sample (1 μg/μL) was used for label-free quantification LFQ in the Mass Spectrometry and Proteomics Core Facility in the University of Nebraska Medical Center (UNMC) as previously described [15].

Protein identification was performed by searching MS/MS data against the Swiss-Prot Homo sapiens protein database downloaded in October 2023 using the in-house PEAKS X + DB search engine. Homo sapiens protein database was used in this study to be able to identify mushroom proteins having similar structure and functions to those present in humans. The search was set for full tryptic peptides with a maximum of 2 missed cleavage sites. Variable modifications were acetylation of protein N-terminus and oxidized methionine, while carbamidomethylation of cysteine was set as a fixed modification. The precursor mass tolerance threshold was set 10 ppm and the maximum fragment mass error was 0.02 Da. The significance threshold of the ion score was calculated based on a false discovery rate (FDR) of ≤ 1%. Quantitative data analysis was performed to determine differentially expressed proteins between 2 different mushroom species using Progenesis QI Proteomics 4.2 (Nonlinear Dynamics).

Statistical analysis was performed using Student’s t-test and FDR and controlled using the Benjamini-Hochberg (BH) method [16]. P value (computed from the proteomics core) and absolute fold changes were used to identify differentially expressed proteins. A protein was differentially expressed if the p value ≤ 0.05 and the absolute fold change ≥ 2. Unique proteins of each species were identified. We used Ingenuity Pathway Analysis (IPA, Qiagen) to identify the pathways and networks in maitake compared to agarikon. We also conducted functional and pathway enrichment analyses using Cytoscape in conjunction with the plug-in ClueGO to identify the enriched biological processes, cellular components, molecular functions, immune responses, Reactome pathways, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. To assess the protein-protein interactions (PPIs), the search tool for the retrieval of interacting genes/proteins (STRING) local network cluster enrichment was conducted using Cytoscape in conjunction with the plug-in STRING Enrichment.

Statistical analysis

For volcano plot and differential expression analysis summary, the p value threshold was 0.05 and absolute fold change threshold was 2. The IPA was performed using the fold change cut-off p value of 0.05. The p value cut-off of 0.05 was also used to select the significantly enriched pathways in both IPA and ClueGO analyses.

Results

Proteins were identified based on the human proteome database. Proteins were considered unique when expressed in one species but not the other. The proteome of agarikon included 117 unique proteins, while that of maitake included 97 proteins (Supplementary file 1). To identify the biological processes and molecular functions related to unique proteins, we performed ClueGO gene ontology (GO) which showed enrichment of beta-tubulin:GTP cofactors, cornified envelope-bound lamellar bodies, aldehyde dehydrogenase, and vascular endothelial growth factor receptor signaling pathways in agarikon (Figure 1A and Supplementary file 2). The protein repertoire unique to maitake showed enrichment of multiple signaling pathways such as phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants, KIT in disease, ERBB2, non-receptor tyrosine kinases, tyrosine-protein kinase 6 (PTK6), mitogen-activated protein kinase 1 (MAPK1)/MAPK3 (Figure 1B and Supplementary file 2).

Figure 1. Pathway enrichment of differentially expressed unique proteins in agarikon and maitake mushrooms.

Figure 1.

Open in a new tab

Gene ontology (GO)-term functional enrichment by 5 categories (immune response, biological process, cellular component, KEGG, and Reactome) performed using Cytoscape in conjunction with the plug-in ClueGO. Enriched signaling pathways of unique proteins for (A) agarikon and (B) maitake.

Principal component analysis (PCA) of samples of both species is shown in Figure 2A. Volcano plot and heatmap depicting differentially expressed proteins in maitake compared to agarikon are shown in Figures 2B and 2C. Out of 134 proteins common to agarikon and maitake, 58 proteins (55 upregulated proteins and 3 downregulated proteins) were significantly changed between the two species (Supplementary file 3). To elucidate the potential protein protective activities, we performed functional and pathway enrichment analysis of maitake against agarikon using IPA. Multiple signaling pathways were found enriched, including BAG co-chaperone 2 (BAG2) (p = 7.94 × 10−12), unfolded protein response (p = 2.24 × 10−4), mitochondrial protein import (p = 1.29 × 10−3), protein ubiquitination (p = 7.94 × 10−11), regulation of apoptosis (p = 2.29 × 10−8), microautophagy (p = 9.55 × 10−7), glycolysis I (p = 1.15 × 10−6), SNAP receptor (SNARE) (p = 8.13 × 10−5), and immunogenic cell death (p = 1.82 × 10−4) (Figure 3 and Supplementary file 4). These results show proteins that delineate immune functions related to potential neuroprotective mechanisms such as autophagy, apoptosis, and glycolysis [17–21]. In Cytoscape ClueGo analysis, the proteins were divided into upregulated and downregulated clusters. The upregulated protein cluster showed enrichment of multiple biological and molecular functions with 50% relationship to Parkinson’s disease (PD) and prion disease (Figure 4A and Supplementary file 5). This suggests that the proteome of agarikon and maitake share common proteins that are related to different biological functions involved in PD and other prion disease processes. In stark contrast, the downregulated protein cluster showed a dominance of Reactome reactions associated with keratin type I and type II interactions (Figure 4B and Supplementary file 5). PPIs were identified related to five categories including biological processes, cellular components, molecular functions, KEGG pathways, and Reactome pathways, and were validated using STRING analysis for interactive networks for both upregulated and downregulated common proteins (Supplementary file 6). Complex interactions of genes involved in biological processes (such as substantia nigra development, protein refolding, and cellular response to unfolded protein); sub-cellular components (such as proteasome complex); molecular functions (such as unfolded protein binding and misfolded protein binding); and KEGG pathways of different neurodegenerative diseases (NDs) including AD, PD, prion disease, and ALS are shown in Supplementary file 6.

Figure 2. Differential proteomic analysis of agarikon and maitake common proteins.

Figure 2.

Open in a new tab

(A) Principal component analysis (PCA) showing the three top components used for proteomic analysis. (B) Volcano plot showing the fold change plotted against the p value highlighting significantly changed proteins in maitake compared to agarikon. Red – upregulation and green –downregulation; p ≤ 0.05 and an absolute fold change ≥ 2. (C) Heatmap showing hierarchical clustering of agarikon and maitake FDR-adjusted proteins. Red – upregulation and green – downregulation. Abbreviations: Sample_A; agarikon, sample_M; maitake.

Figure 3. Pathway enrichment of differentially expressed common proteins in agarikon and maitake mushrooms.

Figure 3.

Open in a new tab

Canonical pathway enrichment analysis of maitake proteome compared to agarikon proteome was performed using IPA (Qiagen). Orange color (activation of pathway), blue color (inhibition of pathway), and grey color (no activity pattern of pathway). The p value ≤ 0.05.

Figure 4. Pathway enrichment of up- and down-regulated common proteins in agarikon and maitake mushrooms.

Figure 4.

Open in a new tab

Enriched signaling pathways of common mushroom proteins that were (A) upregulated or (B) downregulated. Gene ontology (GO)-term functional enrichment by 5 categories (immune response, biological process, cellular component, KEGG, and Reactome) performed using Cytoscape in conjunction with the plug-in ClueGO.

Discussion

Prior studies showed that natural product consumption affects NDs due to protective functions of bioactive molecules in these products [22–24]. Mushrooms possess potent medicinal properties with antioxidant, anti-inflammatory, immunomodulatory, and antimicrobial properties [9, 25]. To our knowledge, the current study is the first to uncover the proteomic signature of mushrooms and their related putative neuroprotective processes. We identified proteins in the fruiting bodies of agarikon and maitake mushrooms. Functional and pathway enrichment analyses of identified proteins in both species uncovered significant enrichment of different signaling pathways related to BAG2, unfolded protein response (UPR), mitochondrial protein import, protein ubiquitination, microautophagy, glycolysis I, SNARE, regulation of apoptosis, and immunogenic cell death. Each alone or together support prior works where polysaccharides, terpenes, phenolic compounds, and vitamins from mushrooms have been shown to potentially affect the onset and progression of NDs [13]. While decades of research have shown that natural compounds produced by living organisms can be at the forefront of new therapeutic discoveries, few have reached basic and clinical affirmations. Mushrooms are well-established to have nutritional and medicinal properties, but have not yet been studied for their potential use in disease treatments, and most notably for those linked to AD. However, products extracted from mushrooms may have beneficial outcomes in AD-related processes and those including the inhibition of acetylcholinesterase and beta-secretase (β-secretase); and the prevention of amyloid beta (Aβ) aggregation and neurotoxicity with linked antioxidant and anti-inflammatory activities [25].

Prions are the hallmarks of degenerative diseases and include alpha-synuclein (α-syn) in PD, and Aβ and Tau in AD. Quality control of proteins plays an important role in protein homeostasis and depends on specific chaperones which regulate the balance between protein folding, assembly, disassembly, translocation, differentiation, and degradation [26]. The co-chaperone BAG2 delivers phosphorylated Tau for degradation to the proteasome in ubiquitin-independent manner in AD models, thus playing a fundamental role in the maintenance of neuronal structure [27]. In addition, stabilization of PTEN-induced kinase 1 (PINK1) by BAG2 triggers Parkin-mediated mitophagy and protects neurons against 1-methyl-4-phenylpyridinium (MPP+)-induced oxidative stress in an in vitro cell model of PD [28]. Agarikon and maitake proteomes were enriched in BAG2 pathway activity with neuroprotective functions.

Defects of mitochondria and endoplasmic reticulum (ER) were reported in different NDs [29, 30]. The main functions of the ER are synthesis and folding of proteins along the secretory pathway, a process mediated by luminal resident chaperones and foldases. The UPR provides a coordinated response that is initiated in the ER and allows the correct folding of proteins [20]. Alterations in ER functions, such as altered calcium levels, increases oxidative stress and/or dysfunction of protein N-glycosylation causing the accumulation of misfolded proteins in the ER, which triggers the ER stress that activates the UPR to augment the ER folding capacity [31]. Two major degradation pathways, the ubiquitin-proteasome system and the autophagy-lysosomal pathway, remove damaged or misfolded proteins to prevent accumulation and maintain homeostasis of cellular proteins [32]. Aging, a primary risk factor of many NDs, is associated with a general reduction in proteasomal degradation and autophagy with the consequent accumulation of potentially neurotoxic protein aggregates of Aβ, Tau, and α-syn [32]. In concert with proteasomal degradation, ubiquitination is associated with degradation signals to process aberrant proteins which form aggregates and lead to neuronal cell damage and death if not chaperoned to the proteasome. Furthermore, autophagy is one of the major intracellular mechanisms to eliminate misfolded proteins and maintain proteostasis [33]. Dysregulated autophagy is increasingly considered to play key roles in most NDs, thus the regulation of autophagy is proposed as a potential therapeutic avenue for these diseases [34, 35]. Coincidentally, agarikon and maitake proteome exhibit proteome pathways that are enriched for protein homeostasis and autophagolysosomal activities.

SNARE proteins are small proteins of around 100–300 amino acids that mediate the fusion of biological membranes by localizing both at the vesicular membrane and on the target membrane [36]. SNARE proteins have fundamental roles in neuronal functions such as neurite initiation and outgrowth, axon specification, axon extension, synaptogenesis, and synaptic transmission [37]. The formation of the SNARE complex was found to be fundamental for vesicle fusion, vesicle recycling, and neurotransmitter release [38]. Inhibition of the formation of the SNARE complex, defects in the SNARE-dependent exocytosis, and altered regulation of SNARE-mediated vesicle fusion were found to be associated with neurodegeneration [39–41]. Agarikon and maitake protein-enriched SNARE signaling pathway supports the mushroom neuroprotective functions.

The brain depends mainly on glucose as a source of energy to maintain normal functions. Aging impairs cerebral glucose metabolism, reduces mitochondrial biogenesis, and decreases ATP levels [42]. Glycolysis and mitochondrial functions are dysregulated in individuals with NDs [43–45]. Decreased glycolytic flux has been shown to correlate with the severity of amyloid and Tau pathology in AD patients [46, 47]. Glycolytic dysfunction has also been observed in PD [18], HD [48], and ALS [49], thus identifying glycolytic dysfunction as a common pathway contributing to neurodegeneration. In general, glycolysis upregulation was found to be neuroprotective in several different NDs [50, 51]. In that vein, agarikon and maitake protein repertoires showed that upregulation of glycolysis offered another possible neuroprotective role.

Immunogenic cell death plays an important role in immunosurveillance by which immune cells look for and recognize foreign pathogens such as bacteria, viruses, or pre-cancerous and cancerous cells in the body [19]. NDs are characterized by progressive loss of particular populations of neurons whereby programmed cell death (apoptosis) has been largely implicated in the pathobiology [52]. The homeostatic maintenance of most organs and tissues is ensured by a controlled balance of cell proliferation and elimination via apoptosis throughout the life of an organism. However, the nervous system is different from most organs because neuronal cell division and proliferation are primarily restricted to embryonic development stage. The threshold required to induce apoptosis becomes much greater once the mature nervous system is established, resulting in markedly less neuronal cell death. Indeed, mature neurons strikingly restrict the apoptosis pathway after development to ensure long-term survival and maintenance throughout life [53]. The protein repertoires of agarikon and maitake comprised proteins linked regulation of immunogenic cell death and apoptosis which have been shown to serve protective functions for neurons and the entire nervous system. Altogether, with the evaluation of common and unique proteins amongst the agarikon and maitake proteomes, we uncovered signaling pathways and molecular functions that are related to neuroprotective activities in the realm of human signaling pathways. To our knowledge, this study is the first to unravel the mushroom proteome of fungal species and expose proteins involved in mechanisms associated with neuroprotective activities for various NDs.

Supplementary Material

Unique Proteins
MvsA Results
MvsA Results 2
MvsA Results 3
Unique Proteins GO
PPIs

Acknowledgments

The authors thank Zachary Petrover, CSO of Mushroom design (US), and Talia Eisenberg, Director of Beond Ibogaine treatment for trauma and addiction (Mexico), for providing the mushroom species used in this study. The authors would also like to thank the UNMC Proteomics Core Facility for assistance with the proteomic analysis. The authors would also like to thank the UNMC Bioinformatics and Systems Biology Core Facility for bioinformatic analysis. The authors would also like to thank the Vice Chancellor’s Office of the UNMC for Core Facility support.

Research funding

This work was supported by the Frances and Louie Blumkin and Harriet Singer Research Foundations, the Carol Swarts, MD Emerging Neuroscience Research Laboratory; and the Margaret R. Larson Professorship.

Footnotes

Competing interests

No conflicts of interest.

Data availability

All data was presented in this manuscript. Proteomic raw data and pathway analyses data are included in supplementary data files.

References

  • [1].Feigin VL et al. , “The global burden of neurological disorders: translating evidence into policy,” Lancet Neurol, vol. 19, no. 3, pp. 255–265, Mar 2020, doi: 10.1016/S1474-4422(19)30411-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [2].Deb A, Thornton JD, Sambamoorthi U, and Innes K, “Direct and indirect cost of managing alzheimer’s disease and related dementias in the United States,” Expert Rev Pharmacoecon Outcomes Res, vol. 17, no. 2, pp. 189–202, Apr 2017, doi: 10.1080/14737167.2017.1313118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [3].Al-Obaidi JR, “Proteomics of edible mushrooms: A mini-review,” Electrophoresis, vol. 37, no. 10, pp. 1257–63, May 2016, doi: 10.1002/elps.201600031. [DOI] [PubMed] [Google Scholar]
  • [4].Obodai M et al. , “Evaluation of the chemical and antioxidant properties of wild and cultivated mushrooms of Ghana,” Molecules, vol. 19, no. 12, pp. 19532–48, Nov 26 2014, doi: 10.3390/molecules191219532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Muszynska B, Grzywacz-Kisielewska A, Kala K, and Gdula-Argasinska J, “Anti-inflammatory properties of edible mushrooms: A review,” Food Chem, vol. 243, pp. 373–381, Mar 15 2018, doi: 10.1016/j.foodchem.2017.09.149. [DOI] [PubMed] [Google Scholar]
  • [6].Nowakowski P, Markiewicz-Zukowska R, Bielecka J, Mielcarek K, Grabia M, and Socha K, “Treasures from the forest: Evaluation of mushroom extracts as anti-cancer agents,” Biomed Pharmacother, vol. 143, p. 112106, Nov 2021, doi: 10.1016/j.biopha.2021.112106. [DOI] [PubMed] [Google Scholar]
  • [7].Uttara B, Singh AV, Zamboni P, and Mahajan RT, “Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options,” Curr Neuropharmacol, vol. 7, no. 1, pp. 65–74, Mar 2009, doi: 10.2174/157015909787602823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [8].Valverde ME, Hernandez-Perez T, and Paredes-Lopez O, “Edible mushrooms: improving human health and promoting quality life,” Int J Microbiol, vol. 2015, p. 376387, 2015, doi: 10.1155/2015/376387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [9].Rai SN, Mishra D, Singh P, Vamanu E, and Singh MP, “Therapeutic applications of mushrooms and their biomolecules along with a glimpse of in silico approach in neurodegenerative diseases,” Biomed Pharmacother, vol. 137, p. 111377, May 2021, doi: 10.1016/j.biopha.2021.111377. [DOI] [PubMed] [Google Scholar]
  • [10].Lai CS, Yu MS, Yuen WH, So KF, Zee SY, and Chang RC, “Antagonizing beta-amyloid peptide neurotoxicity of the anti-aging fungus Ganoderma lucidum,” Brain Res, vol. 1190, pp. 215–24, Jan 23 2008, doi: 10.1016/j.brainres.2007.10.103. [DOI] [PubMed] [Google Scholar]
  • [11].Zhang R, Xu S, Cai Y, Zhou M, Zuo X, and Chan P, “Ganoderma lucidum Protects Dopaminergic Neuron Degeneration through Inhibition of Microglial Activation,” Evid Based Complement Alternat Med, vol. 2011, p. 156810, 2011, doi: 10.1093/ecam/nep075. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [12].Sabaratnam V, Kah-Hui W, Naidu M, and Rosie David P, “Neuronal health - can culinary and medicinal mushrooms help?,” J Tradit Complement Med, vol. 3, no. 1, pp. 62–8, Jan 2013, doi: 10.4103/2225-4110.106549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Tong Z et al. , “Multiple Metabolites Derived from Mushrooms and Their Beneficial Effect on Alzheimer’s Diseases,” Nutrients, vol. 15, no. 12, Jun 15 2023, doi: 10.3390/nu15122758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [14].Li Z, Luo R, Zhang Y, Yan X, and Pang Q, “Effective protein extraction from mycelium and fruiting body of Auricularia auricula for proteomics studies,” International Journal of Food Properties, vol. 21, no. 1, pp. 2156–2166, 2018/01/01 2018, doi: 10.1080/10942912.2018.1499111. [DOI] [Google Scholar]
  • [15].Gao L et al. , “Functional, proteomic and bioinformatic analyses of Nrf2- and Keap1- null skeletal muscle,” J Physiol, vol. 598, no. 23, pp. 5427–5451, Dec 2020, doi: 10.1113/JP280176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Benjamini Y and Hochberg Y, “Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing,” Journal of the Royal Statistical Society: Series B (Methodological), vol. 57, no. 1, pp. 289–300, 1995, doi: 10.1111/j.2517-6161.1995.tb02031.x. [DOI] [Google Scholar]
  • [17].Lima RS, Carrettiero DC, and Ferrari MFR, “BAG2 prevents Tau hyperphosphorylation and increases p62/SQSTM1 in cell models of neurodegeneration,” Mol Biol Rep, vol. 49, no. 8, pp. 7623–7635, Aug 2022, doi: 10.1007/s11033-022-07577-w. [DOI] [PubMed] [Google Scholar]
  • [18].Cai R et al. , “Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases,” J Clin Invest, vol. 129, no. 10, pp. 4539–4549, Oct 1 2019, doi: 10.1172/JCI129987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [19].Kroemer G, Galassi C, Zitvogel L, and Galluzzi L, “Immunogenic cell stress and death,” Nat Immunol, vol. 23, no. 4, pp. 487–500, Apr 2022, doi: 10.1038/s41590-022-01132-2. [DOI] [PubMed] [Google Scholar]
  • [20].Costa CAD, Manaa WE, Duplan E, and Checler F, “The Endoplasmic Reticulum Stress/Unfolded Protein Response and Their Contributions to Parkinson’s Disease Physiopathology,” Cells, vol. 9, no. 11, Nov 17 2020, doi: 10.3390/cells9112495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [21].Margiotta A, “Role of SNAREs in Neurodegenerative Diseases,” Cells, vol. 10, no. 5, Apr 23 2021, doi: 10.3390/cells10050991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [22].Feng J et al. , “Oxidative stress, the blood-brain barrier and neurodegenerative diseases: The critical beneficial role of dietary antioxidants,” Acta Pharm Sin B, vol. 13, no. 10, pp. 3988–4024, Oct 2023, doi: 10.1016/j.apsb.2023.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Pizzino G et al. , “Oxidative Stress: Harms and Benefits for Human Health,” Oxid Med Cell Longev, vol. 2017, p. 8416763, 2017, doi: 10.1155/2017/8416763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [24].Di Paolo M, Papi L, Gori F, and Turillazzi E, “Natural Products in Neurodegenerative Diseases: A Great Promise but an Ethical Challenge,” Int J Mol Sci, vol. 20, no. 20, Oct 18 2019, doi: 10.3390/ijms20205170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [25].Trovato Salinaro A et al. , “Neuroinflammation and neurohormesis in the pathogenesis of Alzheimer’s disease and Alzheimer-linked pathologies: modulation by nutritional mushrooms,” Immun Ageing, vol. 15, p. 8, 2018, doi: 10.1186/s12979-017-0108-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [26].Qin L, Guo J, Zheng Q, and Zhang H, “BAG2 structure, function and involvement in disease,” Cell Mol Biol Lett, vol. 21, p. 18, 2016, doi: 10.1186/s11658-016-0020-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Carrettiero DC, Hernandez I, Neveu P, Papagiannakopoulos T, and Kosik KS, “The cochaperone BAG2 sweeps paired helical filament- insoluble tau from the microtubule,” J Neurosci, vol. 29, no. 7, pp. 2151–61, Feb 18 2009, doi: 10.1523/JNEUROSCI.4660-08.2009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [28].Qu D et al. , “BAG2 Gene-mediated Regulation of PINK1 Protein Is Critical for Mitochondrial Translocation of PARKIN and Neuronal Survival,” J Biol Chem, vol. 290, no. 51, pp. 30441–52, Dec 18 2015, doi: 10.1074/jbc.M115.677815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [29].Johri A and Beal MF, “Mitochondrial dysfunction in neurodegenerative diseases,” J Pharmacol Exp Ther, vol. 342, no. 3, pp. 619–30, Sep 2012, doi: 10.1124/jpet.112.192138. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Wilson EL and Metzakopian E, “ER-mitochondria contact sites in neurodegeneration: genetic screening approaches to investigate novel disease mechanisms,” Cell Death Differ, vol. 28, no. 6, pp. 1804–1821, Jun 2021, doi: 10.1038/s41418-020-00705-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Harding HP, Zhang Y, and Ron D, “Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase,” Nature, vol. 397, no. 6716, pp. 271–4, Jan 21 1999, doi: 10.1038/16729. [DOI] [PubMed] [Google Scholar]
  • [32].Schmidt MF, Gan ZY, Komander D, and Dewson G, “Ubiquitin signalling in neurodegeneration: mechanisms and therapeutic opportunities,” Cell Death Differ, vol. 28, no. 2, pp. 570–590, Feb 2021, doi: 10.1038/s41418-020-00706-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [33].Le Guerroue F and Youle RJ, “Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective,” Cell Death Differ, vol. 28, no. 2, pp. 439–454, Feb 2021, doi: 10.1038/s41418-020-00667-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [34].Menzies FM, Fleming A, and Rubinsztein DC, “Compromised autophagy and neurodegenerative diseases,” Nat Rev Neurosci, vol. 16, no. 6, pp. 345–57, Jun 2015, doi: 10.1038/nrn3961. [DOI] [PubMed] [Google Scholar]
  • [35].Menzies FM, Moreau K, and Rubinsztein DC, “Protein misfolding disorders and macroautophagy,” Curr Opin Cell Biol, vol. 23, no. 2, pp. 190–7, Apr 2011, doi: 10.1016/j.ceb.2010.10.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [36].Holz RW and Zimmerberg J, “Dynamic Relationship of the SNARE Complex with a Membrane,” Biophys J, vol. 117, no. 4, pp. 627–630, Aug 20 2019, doi: 10.1016/j.bpj.2019.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [37].Urbina FL and Gupton SL, “SNARE-Mediated Exocytosis in Neuronal Development,” Front Mol Neurosci, vol. 13, p. 133, 2020, doi: 10.3389/fnmol.2020.00133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [38].Han J, Pluhackova K, and Bockmann RA, “The Multifaceted Role of SNARE Proteins in Membrane Fusion,” Front Physiol, vol. 8, p. 5, 2017, doi: 10.3389/fphys.2017.00005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [39].Almandoz-Gil L, Persson E, Lindstrom V, Ingelsson M, Erlandsson A, and Bergstrom J, “In Situ Proximity Ligation Assay Reveals Co-Localization of Alpha-Synuclein and SNARE Proteins in Murine Primary Neurons,” Front Neurol, vol. 9, p. 180, 2018, doi: 10.3389/fneur.2018.00180. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [40].Law C, Schaan Profes M, Levesque M, Kaltschmidt JA, Verhage M, and Kania A, “Normal Molecular Specification and Neurodegenerative Disease-Like Death of Spinal Neurons Lacking the SNARE-Associated Synaptic Protein Munc18–1,” J Neurosci, vol. 36, no. 2, pp. 561–76, Jan 13 2016, doi: 10.1523/JNEUROSCI.1964-15.2016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [41].Pham E et al. , “Progressive accumulation of amyloid-beta oligomers in Alzheimer’s disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins,” FEBS J, vol. 277, no. 14, pp. 3051–67, Jul 2010, doi: 10.1111/j.1742-4658.2010.07719.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [42].Hoyer S, “Brain glucose and energy metabolism during normal aging,” Aging (Milano), vol. 2, no. 3, pp. 245–58, Sep 1990, doi: 10.1007/BF03323925. [DOI] [PubMed] [Google Scholar]
  • [43].Bhatia S, Rawal R, Sharma P, Singh T, Singh M, and Singh V, “Mitochondrial Dysfunction in Alzheimer’s Disease: Opportunities for Drug Development,” Curr Neuropharmacol, vol. 20, no. 4, pp. 675–692, 2022, doi: 10.2174/1570159X19666210517114016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [44].Bustamante-Barrientos FA et al. , “Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells,” J Transl Med, vol. 21, no. 1, p. 613, Sep 9 2023, doi: 10.1186/s12967-023-04493-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [45].Schapira AH, “Mitochondrial complex I deficiency in Parkinson’s disease,” Adv Neurol, vol. 60, pp. 288–91, 1993. [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/8420145. [PubMed] [Google Scholar]
  • [46].Querfurth HW and LaFerla FM, “Alzheimer’s disease,” N Engl J Med, vol. 362, no. 4, pp. 329–44, Jan 28 2010, doi: 10.1056/NEJMra0909142. [DOI] [PubMed] [Google Scholar]
  • [47].Serrano-Pozo A, Frosch MP, Masliah E, and Hyman BT, “Neuropathological alterations in Alzheimer disease,” Cold Spring Harb Perspect Med, vol. 1, no. 1, p. a006189, Sep 2011, doi: 10.1101/cshperspect.a006189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48].Dubinsky JM, “Towards an Understanding of Energy Impairment in Huntington’s Disease Brain,” J Huntingtons Dis, vol. 6, no. 4, pp. 267–302, 2017, doi: 10.3233/JHD-170264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [49].Tefera TW, Steyn FJ, Ngo ST, and Borges K, “CNS glucose metabolism in Amyotrophic Lateral Sclerosis: a therapeutic target?,” Cell Biosci, vol. 11, no. 1, p. 14, Jan 11 2021, doi: 10.1186/s13578-020-00511-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [50].Manzo E et al. , “Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS,” Elife, vol. 8, Jun 10 2019, doi: 10.7554/eLife.45114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [51].Takahashi S, “Neuroprotective Function of High Glycolytic Activity in Astrocytes: Common Roles in Stroke and Neurodegenerative Diseases,” Int J Mol Sci, vol. 22, no. 12, Jun 18 2021, doi: 10.3390/ijms22126568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [52].Erekat NS, “Apoptosis and its therapeutic implications in neurodegenerative diseases,” Clin Anat, vol. 35, no. 1, pp. 65–78, Jan 2022, doi: 10.1002/ca.23792. [DOI] [PubMed] [Google Scholar]
  • [53].Kole AJ, Annis RP, and Deshmukh M, “Mature neurons: equipped for survival,” Cell Death Dis, vol. 4, no. 6, p. e689, Jun 27 2013, doi: 10.1038/cddis.2013.220. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Unique Proteins
NIHMS2071445-supplement-Unique_Proteins.xlsx (21.3KB, xlsx)
MvsA Results
NIHMS2071445-supplement-MvsA_Results.xlsx (43.6KB, xlsx)
MvsA Results 2
NIHMS2071445-supplement-MvsA_Results_2.xls (101.5KB, xls)
MvsA Results 3
NIHMS2071445-supplement-MvsA_Results_3.xls (268.5KB, xls)
Unique Proteins GO
NIHMS2071445-supplement-Unique_Proteins_GO.xls (633.5KB, xls)
PPIs
NIHMS2071445-supplement-PPIs.xls (209KB, xls)

Data Availability Statement

All data was presented in this manuscript. Proteomic raw data and pathway analyses data are included in supplementary data files.

RESOURCES